NCT04133233 - Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

May 20, 2022

Study Completion Date

July 20, 2022

Conditions

Bipolar Depression

Interventions

DRUG

ILT101

Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)

DRUG

Placebos

Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)

Trial Locations (1)

94010

Pr Marion Leboyer, Créteil